Treating patients who have both multiple sclerosis (MS) and Type 1 diabetes presents unique challenges for physicians, particularly during disease flares. The coexistence of these two autoimmune disorders is an example of polyautoimmunity, a condition where an individual develops more than one autoimmune disease. Studies indicate that up to 30% of people with one autoimmune disorder may eventually develop another. Risk factors include a family history of autoimmune diseases, being female, and having a longer duration of the initial illness.
Autoimmune diseases occur when the immune system attacks the body’s own tissues. In Type 1 diabetes, immune cells destroy insulin-producing cells in the pancreas. In MS, immune cells target the protective covering around nerve fibers in the brain and spinal cord.
Managing treatment becomes complicated because therapies effective for one condition can worsen the other. For instance, intravenous steroids are commonly used to treat MS flares by reducing inflammation. However, these medications can raise blood sugar levels and disrupt insulin metabolism, which poses serious risks for people with Type 1 diabetes. This includes diabetic ketoacidosis—a dangerous situation where lack of insulin causes fat breakdown and acid buildup in the blood.
“Faced with two dangerous outcomes, the challenge for the doctor becomes finding a point of balance,” according to experts from UCLA Health Sciences Media Relations. “They need to suppress the immune attack that is driving the MS flare without disturbing the metabolic control needed to regulate blood sugar.”
To manage this risk when IV steroids are necessary, hospital care is required with close monitoring of ketones and electrolytes along with frequent adjustments to insulin dosages during and after treatment.
“Treating two autoimmune diseases at the same time amplifies the level of care needed to stay safe,” according to guidance from UCLA Health Sciences Media Relations. “With careful planning, including coordinated care for both conditions, vigilant glucose management before MS treatment and clear guidance about warning signs, this risk can be managed.”
Patients are encouraged to seek coordinated medical care and remain alert to changes in their health status.
For questions or concerns related to managing coexisting autoimmune conditions, individuals may contact Ask the Doctors at [email protected] or write to UCLA Health Sciences Media Relations.
